AMICUS THERAPEUTICS, INC. — Director's Dealing 2015

Jul 15, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2015-07-13

Reporting Person: Crowley John F (Director, Chairman & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2015-07-13	Common Stock	M	7750	$15.0084	Acquired	91249	Direct
2015-07-13	Common Stock	S	7750	$15.0084	Disposed	83499	Direct
2015-07-14	Common Stock	M	142250	$15.0276	Acquired	225749	Direct
2015-07-14	Common Stock	S	142250	$15.0276	Disposed	83499	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-07-13	Stock Options (right to buy)	$4.16	M	7750	Disposed	2019-11-16	Common Stock (7750)	Direct
2015-07-14	Stock Options (right to buy)	$4.16	M	142250	Disposed	2019-11-16	Common Stock (142250)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	64895	Indirect

Footnotes

F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.

F2: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.00 to $15.06. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F3: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.00 to $15.06. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

F4: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.00 to $15.10. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F5: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.00 to $15.10. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.